Skip to main content



14-06-2019 | Rheumatology | News | Article

Safety profile of nintedanib similar in SSc–ILD, IPF

Nintedanib’s safety and tolerability profile is similar in patients with systemic sclerosis-associated interstitial lung disease and those with idiopathic pulmonary fibrosis, according to a comparison of data from the SENSCIS and INPULSIS trials.

14-06-2019 | Oncology | News | Article

TAK-788 shows activity against NSCLC with EGFR exon 20 insertions

The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.

14-06-2019 | Rheumatology | News | Article

Pirfenidone disappoints in SSc–ILD trial

Randomized trial findings presented at the EULAR 2019 congress in Madrid, Spain, suggest that pirfenidone does not stabilize or improve lung function in patients with systemic sclerosis-associated interstitial lung disease.

13-06-2019 | Oncology | News | Article

BLU-667 active against RET fusion-positive advanced NSCLC

Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.

11-06-2019 | Oncology | News | Article

RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

07-06-2019 | Oncology | News | Article

Prolonged survival possible with pembrolizumab in advanced NSCLC

Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.

05-06-2019 | Asthma | News | Article

Physicians often underestimate asthma control levels

Researchers have found that physicians often underestimate the level of asthma control in patients.

29-05-2019 | Oncology | News | Article

First-line atezolizumab–chemotherapy an option for nonmutated metastatic NSCLC

Patients with treatment-naïve, nonmutated, nonsquamous, advanced non-small-cell lung cancer derive a significant survival benefit from the addition of the PD-L1 inhibitor atezolizumab to chemotherapy, indicate phase III trial findings.

24-05-2019 | Oncology | News | Article

Twice-daily radiotherapy may increase brain metastasis risk in SCLC

Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.

20-05-2019 | Rheumatology | News | Article

Nintedanib slows lung function decline in SSc-associated interstitial lung disease

Findings from the SENSCIS trial indicate that the tyrosine kinase inhibitor nintedanib reduces the annual rate of decline in forced vital capacity among patients with systemic sclerosis-associated interstitial lung disease.

17-05-2019 | Oncology | News | Article

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

14-05-2019 | Oncology | News | Article

Whole-body MRI staging quicker and cheaper than standard pathways in NSCLC

The Streamline L trial has found that in patients with newly diagnosed non-small-cell lung cancer, a staging pathway using whole-body magnetic resonance imaging has similar accuracy but a shorter time to complete staging and lower mean per-patient costs versus standard pathways.

13-05-2019 | Oncology | News | Article

Local consolidative therapy improves oligometastatic NSCLC survival

Patients with stage IV non-small-cell lung cancer and no more than three metastases derive an overall survival benefit from aggressive local consolidative therapy, suggest trial results.

29-04-2019 | Lung cancer | News | Article

ALESIA backs first-line alectinib in Asian NSCLC patients

Previously untreated Asian patients with advanced ALK translocation-positive non-small-cell lung cancer derive a significant progression-free survival benefit from alectinib over crizotinib, indicate phase III trial results.

08-04-2019 | Asthma | News | Article

Prevalence of severe eosinophilic asthma estimated in Japan

Approximately one third of patients with severe asthma in Japan have severe eosinophilic asthma, show findings from a cohort analysis.

28-03-2019 | Asthma | News | Article

Greater consideration of small airways dysfunction warranted in asthma management

Small airways dysfunction occurs across all degrees of asthma severity but has the highest prevalence among individuals with the most severe disease, suggest baseline findings from the ATLANTIS study.

21-03-2019 | Respiratory | News | Article

Pirfenidone a ‘feasible treatment option’ for advanced IPF

A post-hoc analysis of the RECAP study suggests that pirfenidone-treated patients with idiopathic pulmonary fibrosis experience similar rates of lung function decline irrespective of whether they have more or less advanced disease.

14-03-2019 | Asthma | News | Article

Chronic cough may point to more severe asthma phenotype

Among patients with asthma, those with chronic cough have worse respiratory symptoms and lung function, and higher levels of some inflammatory markers, than those without, study findings indicate.

07-03-2019 | Respiratory | News | Article

No survival benefit of add-on cyclophosphamide following IPF exacerbation

The addition of intravenous cyclophosphamide to corticosteroid treatment is not associated with significantly improved survival among patients with an acute exacerbation of idiopathic pulmonary fibrosis, researchers report.

28-02-2019 | Respiratory | News | Article

Antifibrinolytic therapy reduces haemoptysis admission in cystic fibrosis

Systemic antifibrinolytic therapy could help to reduce haemoptysis hospital admissions among patients with cystic fibrosis, suggests research.

Image Credits